Stem cells as an ideal carrier for gene therapy: A new approach to the treatment of hepatitis C virus.
Rafati A, Esmaeili Gouvarchin Ghaleh H, Azarabadi A, Masoudi MR, Afrasiab E, Ghorbani Alvanegh A.
Transpl Immunol. 2022 Dec;75:101721. doi: 10.1016/j.trim.2022.101721. Epub 2022 Sep 20.
Maternal hepatitis B or C carrier status and long-term risk for offspring neurological morbidity: a population-based cohort study.
Yoles I, Sheiner E, Abu-Freha N, Wainstock T.
J Dev Orig Health Dis. 2022 Feb;13(1):115-119. doi: 10.1017/S2040174420001397. Epub 2021 Jan 21.
Maternal hepatitis B or hepatitis C virus carrier status and long-term infectious morbidity of the offspring: A population-based cohort study.
Abu Freha N, Wainstock T, Poupko L, Yonat Shemer A, Sergienko R, Sheiner E.
J Viral Hepat. 2020 Aug;27(8):794-799. doi: 10.1111/jvh.13300. Epub 2020 May 3.
Hepatitis C Vaccine: 10 Good Reasons for Continuing.
Roingeard P, Beaumont E.
Hepatology. 2020 May;71(5):1845-1850. doi: 10.1002/hep.31182.
Hepatitis C: the next 25years.
Houghton M.
Antiviral Res. 2014 Oct;110:77-8. doi: 10.1016/j.antiviral.2014.06.018. Epub 2014 Jul 17.
Animal models for hepatitis C.
Billerbeck E, de Jong Y, Dorner M, de la Fuente C, Ploss A.
Curr Top Microbiol Immunol. 2013;369:49-86. doi: 10.1007/978-3-642-27340-7_3.
Chronic hepatitis C virus infection and lipoprotein metabolism.
Aizawa Y, Seki N, Nagano T, Abe H.
World J Gastroenterol. 2015 Sep 28;21(36):10299-313. doi: 10.3748/wjg.v21.i36.10299.
Changing terminology of hepatitis B and C carrier: consensus statement. Indian Association for Study of the Liver (INASL).
[No authors listed]
Indian J Gastroenterol. 1999 Mar;18 Suppl 1:S15-20.
Hepatitis C virus carriers with persistently normal aminotransferase levels: healthy people or true patients?
Puoti C, Castellacci R, Montagnese F.
Dig Liver Dis. 2000 Oct;32(7):634-43. doi: 10.1016/s1590-8658(00)80850-6.
[Hepatitis C].
Gattoni A, Cecere A, Caiazzo R, Romano C.
Clin Ter. 1996 Sep;147(9):413-38.
